Eleuzis

Eleusis is a clinical-stage life sciences company that develops psychedelic drugs into mainstream medicines. Founded in 2013 by Shlomi Raz and Charles D. Nichols in London, United Kingdom, it was the first company to develop psychedelic drugs as medicines. Raz, a former Goldman Sachs managing director, serves as the company's CEO, while Nichols, a psychedelic pharmacologist, is its lead scientist. The company was named after the Eleusinian Mysteries, an ancient Greek religious cult.

The firm's primary focus is on developing serotonin 5-HT2A receptor agonists, which are related to serotonergic psychedelics, as novel anti-inflammatory drugs. Eleusis has created a portfolio of drug candidates aimed at addressing unmet needs in psychiatry and beyond. Its lead drug candidate, ELE-Psilo, is a proprietary psilocybin-based drug formulated for IV infusion for the treatment of depression. Other candidates include ELE-02, a topical eye drop for inflammatory eye conditions, and research into using LSD microdosing for Alzheimer's disease.

Eleusis operates on a business model centered on the discovery and development of its drug candidates, with the goal of making them compatible with existing healthcare infrastructure and insurance reimbursement requirements. The company has raised a total of $1.47M in funding over three rounds from six institutional investors. In October 2022, Eleusis was acquired by Beckley Psytech.

Keywords: psychedelic medicine, life sciences, drug discovery, neuroprotective medicines, immunomodulatory, psilocybin, depression treatment, anti-inflammatory drugs, serotonin receptor agonists, clinical-stage, Alzheimer's research, IV infusion therapy, ophthalmology, drug development, Beckley Psytech, Shlomi Raz, Charles D. Nichols, ELE-Psilo, psychedelic therapeutics, mental health treatment